{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"acute-myeloid-leukemia-and-myelodysplastic-syndromes-related-to-alkylating-agent","columns":[],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":[],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":[],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":0,"emptyColumnKeys":[],"hpoRelease":"not available","narrativeSourceChanges":[],"records":0,"sourceGroups":{}},"features":[],"ledeHtml":"Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent is a subgroup of therapy-related myeloid neoplasms (t-MN), associated with a treatment of an unrelated neoplastic or autoimmune disease with cytotoxic agents, like cyclophosphamid, platins, melphalan and others. The neoplastic cells typically harbor unbalanced aberrations of chromosomes 5 and 7 (monosomy 5/del(5q) and monosomy 7/del(7q)) or a complex karyotype. It usually presents with multilineage dysplasia and cytopenias 5-10 years after exposure, with symptoms related to the degree of bone marrow failure and the corresponding cytopenia (fatigue, bleeding and bruising, recurrent infections, bone pain).","mondoId":"MONDO:0015164","node":{"canonicalSlug":"acute-myeloid-leukemia-and-myelodysplastic-syndromes-related-to-alkylating-agent","comparisons":[],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"definition-only","matchMethod":"same-ontology-node","name":"acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent","paragraphs":["Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent is a subgroup of therapy-related myeloid neoplasms (t-MN), associated with a treatment of an unrelated neoplastic or autoimmune disease with cytotoxic agents, like cyclophosphamid, platins, melphalan and others. The neoplastic cells typically harbor unbalanced aberrations of chromosomes 5 and 7 (monosomy 5/del(5q) and monosomy 7/del(7q)) or a complex karyotype. It usually presents with multilineage dysplasia and cytopenias 5-10 years after exposure, with symptoms related to the degree of bone marrow failure and the corresponding cytopenia (fatigue, bleeding and bruising, recurrent infections, bone pain)."],"scope":"exact","source":"MONDO","upstream":"Orphanet:102379","url":"https://monarchinitiative.org/MONDO:0015164"},"ownColumnKeys":[],"publication":"published","relationships":[{"kind":"parent","label":"therapy related acute myeloid leukemia and myelodysplastic syndrome","mondoId":"MONDO:0019457","slug":"therapy-related-acute-myeloid-leukemia-and-myelodysplastic"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[{"reason":"Public source record is not available in the frozen inputs","source":"GARD","url":"https://rarediseases.info.nih.gov/diseases/19835"}],"translation":"pending"},"records":[],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0015164\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>definition-only</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>same-ontology-node</dd><dt>Upstream attribution</dt><dd>Orphanet:102379</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent is a subgroup of therapy-related myeloid neoplasms (t-MN), associated with a treatment of an unrelated neoplastic or autoimmune disease with cytotoxic agents, like cyclophosphamid, platins, melphalan and others. The neoplastic cells typically harbor unbalanced aberrations of chromosomes 5 and 7 (monosomy 5/del(5q) and monosomy 7/del(7q)) or a complex karyotype. It usually presents with multilineage dysplasia and cytopenias 5-10 years after exposure, with symptoms related to the degree of bone marrow failure and the corresponding cytopenia (fatigue, bleeding and bruising, recurrent infections, bone pain).</p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0015164\" rel=\"noreferrer\">MONDO</a></p>","key":"overview","title":"Brief description"}],"sharedSources":[],"slug":"acute-myeloid-leukemia-and-myelodysplastic-syndromes-related-to-alkylating-agent","sourceDocuments":[{"name":"MONDO: acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0015164"}],"sourceNote":"","synonyms":["AML and myelodysplastic syndromes related to alkylating agent"],"takeawayHtml":"","title":"acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent"},"schemaVersion":1}
